

PRESS RELEASE

U-Protein Express and Podiceps receive FND Feasibility grant for the development of human biomarkers to study metabolic syndrome.

Utrecht, the Netherlands, November 29th, 2007 – U-Protein Express B.V., a Dutch private developer and producer of recombinant proteins based in Utrecht, has received a first feasibility grant from the FND programme to develop human biomarkers that will be further studied in collaboration with Podiceps and the T1 Food & Nutrition and validated in human studies.

Major research investments in nutrigenomics have provided exciting new avenues for improved understanding of the relation between nutrition and health. In order to capitalize on these developments, there is a need to translate these huge amounts of know-how and data into useable technology for the food industries. At the applied industrial level the ambition is to demonstrate that indispensable phenotype information from human intervention studies can be extracted and thereby the development of new food products with substantial health benefits can be facilitated. Product innovation and claim substantiation is essential for the Dutch food industry to stay competitive and profitable in a global market.

Contact:

Martin Hessing, CEO
Tel: +31 (0)622466793

E-mail: m.hessing@U-proteinexpress.com
Website: www.U-Proteinexpress.com